Galecto Biotech

Last updated: July 31, 2025

Hans Schambye - Co-Founder & CEO
Hans Schambye - Co-Founder & CEO
Denmark | Funding: $160.4M (+)

Website: https://galecto.com

Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.